• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Healthcare·ALIMP.PA
Share

Implanet S.A. Stocks

€ 0.18Last Updated 04.09.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

€ 29.83M

€ 0.18
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

05.09.2026 23:47

The U.S. struck three Iranian oil tankers in response to an attack on its aircraft carrier

05.09.2026 16:01

Small-Cap Highlights: Betting on Marc Jacobs, GoPro's Outlook, the Dropbox Hack

05.09.2026 13:01

Oil is nearing $100, the Fed is easing market jitters, and Nvidia is acquiring Hugging Face

05.09.2026 03:39

It lacked drama: Analysts explain Tesla's stock plunge following the launch of the Cybercab

05.09.2026 03:09

Three companies will be added to the S&P 500 in September. Which companies were removed from the index?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026